GleamWall
中文EN

GRCE Grace Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1444192 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-173.9%
TTM EPS YoY-118.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-36.2%
ROA-34.5%
ROIC (approx.)-46.7%
Asset turnover—

Leverage & solvency

Liabilities / assets3.8%
Debt / equity0.00x
Current ratio13.61x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.42x
Accruals ratio-20.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31
Income statement
Revenue——
R&D expense$2.40M$9.51M
SG&A expense$8.67M$7.17M
Operating income-$11.08M-$16.68M
Pretax income-$9.49M-$12.77M
Income tax-$1.70M-$3.20M
Net income-$7.79M-$9.57M
EBITDA-$11.07M-$16.67M
EPS (basic)-0.47-0.79
EPS (diluted)-0.47-0.79
Weighted avg. shares (diluted)16.51M12.09M
Balance sheet
Cash & equivalents$16.98M$22.13M
Current assets$17.38M$22.71M
PP&E, net$8,000$15,000
Goodwill$8.14M$8.14M
Intangibles$41.13M$41.13M
Total assets$66.65M$71.99M
Current liabilities$2.15M$1.93M
Total liabilities$2.76M$5.38M
Shareholders' equity$63.90M$66.61M
Shares outstanding16.02M13.72M
Cash flow statement
Operating cash flow-$8.87M-$14.90M
Investing cash flow$0$0
Financing cash flow$3.71M$14.03M
Depreciation & amortization$7,000$7,000
Stock-based compensation$798,000$730,000

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.